Skip to main content
. 2017 Dec 22;36:97. doi: 10.1186/s40880-017-0263-y

Fig. 2.

Fig. 2

Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) probability of mCRC patients treated with famitinib and placebo. a the median PFS in the famitinib group was significantly longer than that in the placebo group (P = 0.004); b there is no significant difference in the median OS between the two groups